Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Regenxbio Analyst Ratings and Price Targets | NASDAQ:RGNX | Benzinga
Regenxbio Inc has a consensus price target of $35.19 based on the ratings of 17 analysts. The high is $61 issued by Berenberg on June 23, 2022. The low is $12 issued by Goldman Sachs on April 17, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, Goldman Sachs, and HC Wainwright & Co. on June 9, 2025, April 17, 2025, and March 21, 2025, respectively. With an average price target of $32.67 between Chardan Capital, Goldman Sachs, and HC Wainwright & Co., there's an implied 238.16% upside for Regenxbio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Goldman Sachs
HC Wainwright & Co.
HC Wainwright & Co.
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Regenxbio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/09/2025 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 04/17/2025 | Buy Now | 24.22% | Goldman Sachs | Paul Choi58% | $14 → $12 | Maintains | Neutral | Get Alert |
| 03/21/2025 | Buy Now | 251.97% | HC Wainwright & Co. | Yi Chen61% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 251.97% | HC Wainwright & Co. | Yi Chen61% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 03/17/2025 | Buy Now | 251.97% | HC Wainwright & Co. | Raghuram Selvaraju44% | $36 → $34 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 148.45% | Morgan Stanley | Judah Frommer65% | $22 → $24 | Maintains | Overweight | Get Alert |
| 02/11/2025 | Buy Now | 44.93% | Goldman Sachs | Paul Choi58% | $38 → $14 | Downgrade | Buy → Neutral | Get Alert |
| 01/21/2025 | Buy Now | 210.56% | RBC Capital | Luca Issi46% | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 01/15/2025 | Buy Now | 272.67% | HC Wainwright & Co. | Yi Chen61% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 262.32% | RBC Capital | Luca Issi46% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 272.67% | HC Wainwright & Co. | Yi Chen61% | $40 → $36 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 127.74% | Morgan Stanley | Judah Frommer65% | → $22 | Assumes | → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 314.08% | HC Wainwright & Co. | Yi Chen61% | $39 → $40 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 10/10/2024 | Buy Now | 86.34% | Raymond James | Danielle Brill44% | → $18 | Reinstates | → Outperform | Get Alert |
| 09/04/2024 | Buy Now | 303.73% | HC Wainwright & Co. | Yi Chen61% | $39 → $39 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 417.6% | Barclays | Gena Wang52% | $55 → $50 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 303.73% | HC Wainwright & Co. | Yi Chen61% | $38 → $39 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | 293.37% | HC Wainwright & Co. | Yi Chen61% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 293.37% | Goldman Sachs | Paul Choi58% | → $38 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 293.37% | HC Wainwright & Co. | Yi Chen61% | $36 → $38 | Maintains | Buy | Get Alert |
| 04/12/2024 | Buy Now | 314.08% | Stifel | Annabel Samimy66% | → $40 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 272.67% | HC Wainwright & Co. | Yi Chen61% | → $36 | Initiates | → Buy | Get Alert |
| 03/08/2024 | Buy Now | 262.32% | RBC Capital | Luca Issi46% | $20 → $35 | Upgrade | Sector Perform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 438.3% | Chardan Capital | Daniil Gataulin58% | $52 → $52 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 469.36% | Barclays | Gena Wang52% | $45 → $55 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | — | Leerink Partners | Mani Foroohar50% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 303.73% | Baird | Brian Skorney59% | $34 → $39 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 117.39% | Wedbush | Andreas Argyrides72% | $21 → $21 | Reiterates | Neutral → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 365.84% | Raymond James | Dane Leone45% | → $45 | Reinstates | → Outperform | Get Alert |
| 02/12/2024 | Buy Now | 117.39% | Wedbush | Andreas Argyrides72% | $21 → $21 | Reiterates | Neutral → Neutral | Get Alert |
| 11/01/2023 | Buy Now | 262.32% | Stifel | Annabel Samimy66% | → $35 | Initiates | → Buy | Get Alert |
| 10/05/2023 | Buy Now | 107.04% | Wedbush | Andreas Argyrides72% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 10/04/2023 | Buy Now | 107.04% | RBC Capital | Luca Issi46% | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/29/2023 | Buy Now | 334.78% | Morgan Stanley | Vikram Purohit39% | $43 → $42 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 469.36% | Chardan Capital | Daniil Gataulin58% | → $55 | Reiterates | → Buy | Get Alert |
| 07/12/2023 | Buy Now | 107.04% | RBC Capital | Luca Issi46% | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/20/2023 | Buy Now | 334.78% | Baird | Brian Skorney59% | → $42 | Initiates | → Outperform | Get Alert |
| 06/02/2023 | Buy Now | 334.78% | Baird | Brian Skorney59% | → $42 | Initiates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 345.13% | Morgan Stanley | Vikram Purohit39% | $46 → $43 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 469.36% | Chardan Capital | Daniil Gataulin58% | $61 → $55 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 107.04% | RBC Capital | Luca Issi46% | $22 → $20 | Maintains | Sector Perform | Get Alert |
| 03/06/2023 | Buy Now | 376.19% | Morgan Stanley | Vikram Purohit39% | $50 → $46 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 531.47% | Chardan Capital | Daniil Gataulin58% | → $61 | Reiterates | → Buy | Get Alert |
| 01/23/2023 | Buy Now | 44.93% | SVB Leerink | Mani Foroohar50% | $15 → $14 | Maintains | Market Perform | Get Alert |
| 11/21/2022 | Buy Now | 417.6% | Morgan Stanley | Vikram Purohit39% | $52 → $50 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 531.47% | Chardan Capital | Daniil Gataulin58% | $70 → $61 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 44.93% | SVB Leerink | Mani Foroohar50% | $13 → $14 | Maintains | Market Perform | Get Alert |
| 10/04/2022 | Buy Now | 200.21% | RBC Capital | Luca Issi46% | $47 → $29 | Maintains | Sector Perform | Get Alert |
| 09/09/2022 | Buy Now | 438.3% | Morgan Stanley | Vikram Purohit39% | $46 → $52 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 376.19% | Morgan Stanley | Vikram Purohit39% | $47 → $46 | Maintains | Overweight | Get Alert |
| 06/23/2022 | Buy Now | 531.47% | Berenberg | Caroline Palomeque59% | → $61 | Initiates | → Buy | Get Alert |
| 06/23/2022 | Buy Now | 386.54% | UBS | Eliana Merle49% | $51 → $47 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Regenxbio (RGNX) stock?
The latest price target for Regenxbio (NASDAQ:RGNX) was reported by Chardan Capital on June 9, 2025. The analyst firm set a price target for $52.00 expecting RGNX to rise to within 12 months (a possible 438.30% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regenxbio (RGNX)?
The latest analyst rating for Regenxbio (NASDAQ:RGNX) was provided by Chardan Capital, and Regenxbio maintained their buy rating.
When was the last upgrade for Regenxbio (RGNX)?
The last upgrade for Regenxbio Inc happened on March 8, 2024 when RBC Capital raised their price target to $35. RBC Capital previously had a sector perform for Regenxbio Inc.
When was the last downgrade for Regenxbio (RGNX)?
The last downgrade for Regenxbio Inc happened on February 11, 2025 when Goldman Sachs changed their price target from $38 to $14 for Regenxbio Inc.
When is the next analyst rating going to be posted or updated for Regenxbio (RGNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regenxbio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regenxbio was filed on June 9, 2025 so you should expect the next rating to be made available sometime around June 9, 2026.
Is the Analyst Rating Regenxbio (RGNX) correct?
While ratings are subjective and will change, the latest Regenxbio (RGNX) rating was a maintained with a price target of $52.00 to $52.00. The current price Regenxbio (RGNX) is trading at is $9.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
